2. Metabolic Disease

Metabolic Disease

Metabolic Disease

Related Products

PDF 53.7 MB

Metabolic diseases is defined by a constellation of interconnected physiological, biochemical, clinical, and metabolic factors that directly increases the risk of cardiovascular disease, type 2 diabetes mellitus, and all cause mortality. Associated conditions include hyperuricemia, fatty liver (especially in concurrent obesity) progressing to nonalcoholic fatty liver disease, polycystic ovarian syndrome (in women), erectile dysfunction (in men), and acanthosis nigricans. Metabolic disease modeling is an essential component of biomedical research and a mandatory prerequisite for the treatment of human disease. Somatic genome editing using CRISPR/Cas9 might be used to establish novel metabolic disease models.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-113149
    Argininosuccinic acid 2387-71-5 98%
    Argininosuccinic acid is an intermediate metabolite in the urea cycle, and its level is associated with argininosuccinic aciduria. Argininosuccinic acid can induce oxidative stress, leading to lipid and protein oxidation, reduction of glutathione, and decrease in antioxidant enzyme activity. Argininosuccinic acid can be converted into guanidinosuccinic acid, a nitric oxide mimic, under the action of nitric oxide-derived free radicals. Argininosuccinic acid can be used in the research of metabolic diseases, renal failure, nervous system diseases, etc.
    Argininosuccinic acid
  • HY-113401
    Adenosine 2',3'-cyclic phosphate 634-01-5 98%
    Adenosine 2',3'-cyclic phosphate is a 2',3'-cyclic purine nucleotide. Adenosine 2',3'-cyclic phosphate can be degrade to 2'-AMP and 3'-AMP.
    Adenosine 2',3'-cyclic phosphate
  • HY-113407
    D-Fructose-6-phosphate 643-13-0 98%
    D-Fructose 6-phosphate is an endogenous metabolite in saliva that affects cell growth and autophagy; it can be hydrolyzed by Fructose-1,6-bisphosphatase (FBPase). D-Fructose-6-phosphate can be converted into D-glucose 6-phosphate (HY-112537) by the action of phosphoglucose isomerase. D-Fructose-6-phosphate is a sugar intermediate in the glycolysis pathway and the pentose phosphate pathway. D-Fructose 6-phosphate can be used to study Lewy body dementia.
    D-Fructose-6-phosphate
  • HY-113510
    9(S)-HOTrE 89886-42-0 98%
    9(S)-HOTrE is an ester product.
    9(S)-HOTrE
  • HY-113545
    9(R)-HODE 10075-11-3 98%
    9(R)-HODE is a monohydroxy fatty acid and metabolite of linoleic acid. It is formed from linoleic acid by COX and lipoxygenase (LO).9(R)-HODE induces chemotaxis, increases the levels of chemokine (C-C motif) receptor 9 (CCR9) and chemokine (C-X-C motif) receptor 4 (CXCR4), and inhibits IL-6 release in primary human monocytes. It inhibits CD3α- and CD28-induced proliferation of isolated human peripheral blood lymphocytes when used at a concentration of 25 μg/mL.
    9(R)-HODE
  • HY-113567
    GSK2324 1020567-30-9 98%
    GSK2324 (Compd 1c) is a FXR agonist for diabetes study, with an EC50 of 120 nM. GSK2324 exhibits t1/2 values of 84 min (mouse), 170 min (rat), 110 min (beagle) and 120 min (cyno), respectively.
    GSK2324
  • HY-113655
    AD-5075 103788-05-2 98%
    AD-5075 is an orally active insulin sensitizer. AD-5075 mediates its antidiabetic activity by binding to PPARγ and thereby generating an active conformation of the receptor.
    AD-5075
  • HY-113775
    Octadecanoyl-L-threo-sphingosine 95037-06-2 98%
    Octadecanoyl-L-threo-sphingosine is an ester product.
    Octadecanoyl-L-threo-sphingosine
  • HY-113864
    Diisobutyl carbinol 108-82-7 98%
    Diisobutyl carbinol (DIBC) is an orally active organic solvent widely used as industrial intermediates and fragrance ingredient. Diisobutyl carbinol and Diisobutyl ketone are well interconverted metabolically in rats.
    Diisobutyl carbinol
  • HY-113884
    (R)-Coriolic acid 10219-69-9 98%
    13(R)-HODE is the opposite enantiomer of the 13(S)-HODE produced when linoleic acid is incubated with soybean lipoxygenase. The presence of 13(R)-HODE in the supernatants and membranes of cultured bovine endothelial cells has been attributed to COX metabolism.1 13(R)-HODE is a weak (IC50=2.7 μM) inhibitor of U-46619-induced platelet aggregation.
    (R)-Coriolic acid
  • HY-113925
    1,2-Dilauroyl-sn-glycero-3-phosphate sodium 108321-06-8 98%
    1,2-Dilauroyl-sn-glycero-3-phosphate (1,2-DLPA) sodium is a phospholipid containing the medium-chain (12:0) lauric acid inserted at the sn-1 and sn-2 positions. It can be used in the generation of micelles, liposomes, and other types of artificial membranes.
    1,2-Dilauroyl-sn-glycero-3-phosphate sodium
  • HY-114509
    Anilazine 101-05-3 98%
    Anilazine is a fungicide and inhibit the growth of Rhizobium sp. and E. coli. Anilazine inhibits glucose oxidation and succinate oxidation and also inhibits in vitro succinic dehydrogenase activity.
    Anilazine
  • HY-114635
    Dexecadotril 112573-72-5 98%
    Dexecadotril (Retorphan) is a powerful and selective neprilysin (NEP) inhibitor. Dexecadotril is a prodrug of the R-enantiomers of Thiorphan (HY-W013375). Dexecadotril shows intestinal antisecretatory action.
    Dexecadotril
  • HY-114695
    Prostaglandin F2α-1-glyceryl ester 43042-79-1 98%
    Prostaglandin F2α-1-glyceryl ester can be oxidized by 15-hydroxyprostaglandin dehydrogenase (15-HPGDH).
    Prostaglandin F2α-1-glyceryl ester
  • HY-114700
    ZINC08438472 443872-20-6 98%
    ZINC08438472 is a potent and selective peroxisome proliferator activated receptors-α (PPAR-α) agonist with an EC50 value of 12.1 nM. ZINC08438472 is promising for research of diabetes, hyperlipidaemia and inflammatory disorders.
    ZINC08438472
  • HY-114754
    BemPPOX 1998101-23-7 98%
    BemPPOX is an orally active, potent dog gastric lipase (DGL) inhibitor with Xl50 (the inhibitor molar excess leading to 50% lipase inhibition) of 0.5. BemPPOX is also a good inhibitor of GPLRP2 (xl50=0.64). BemPPOX efficiently regulates the gastrointestinal lipolysis and slows down the overall lipolysis process in rats. BemPPOX has the potential for obesity research.
    BemPPOX
  • HY-114853
    BVT.13 756813-87-3 98%
    BVT.13 is an orally active and selective PPARγ agonist with a maximal efficacy similar to that of Rosiglitazone (HY-17386). In addition, BVT.13 exhibits antidiabetic activity in ob/ob mice.
    BVT.13
  • HY-115014
    Cibenzoline succinate 100678-32-8 98%
    Cibenzoline succinate (Cifenline succinate) is the succinate form of Cibenzoline (HY-106577). Cibenzoline succinate is an inhibitor for ATP-sensitive potassium (KATP) channel by affecting the pore-forming Kir6.2 subunit with IC50 of 22.2 µM. Cibenzoline succinate affects insulin secretion and exhibits antiarrhythmic and antidiabetic activities.
    Cibenzoline succinate
  • HY-115358
    Lignoceroyl Ethanolamide 10015-68-6 98%
    Lignoceroyl ethanolamide is a member of the family of fatty N-acyl ethanolamines collectively called endocannabinoids. Whereas lignoceric acid has been detected at relatively high levels in rat cerebrospinal fluid, the specific role and relative importance of its ethanolamine metabolite have not been determined.
    Lignoceroyl Ethanolamide
  • HY-115410
    NG-Amino-L-arginine hydrochloride 1031799-40-2 98%
    NG-Amino-L-arginine hydrochloride induces inactivation of the citrulline-forming activity of the nNOS, iNOS, and eNOS isoforms with Ki values of 0.3 μM, 3 μM, and 2.5 μM, respectively.
    NG-Amino-L-arginine hydrochloride
Cat. No. Product Name / Synonyms Application Reactivity